MA51311A - Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées - Google Patents

Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Info

Publication number
MA51311A
MA51311A MA051311A MA51311A MA51311A MA 51311 A MA51311 A MA 51311A MA 051311 A MA051311 A MA 051311A MA 51311 A MA51311 A MA 51311A MA 51311 A MA51311 A MA 51311A
Authority
MA
Morocco
Prior art keywords
hbv
vaccines
hepatitis
virus
related uses
Prior art date
Application number
MA051311A
Other languages
English (en)
Inventor
Daniel Boden
Pooter Dorien De
Helen Horton
Jean-Marc Edmond Fernand Marie Neefs
Soumitra Roy
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA51311A publication Critical patent/MA51311A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA051311A 2017-12-19 2018-12-18 Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées MA51311A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607426P 2017-12-19 2017-12-19
IB2017058142 2017-12-19

Publications (1)

Publication Number Publication Date
MA51311A true MA51311A (fr) 2020-10-28

Family

ID=65199441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051311A MA51311A (fr) 2017-12-19 2018-12-18 Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Country Status (15)

Country Link
EP (2) EP4272833A3 (fr)
JP (1) JP7317017B2 (fr)
KR (1) KR20200101416A (fr)
CN (1) CN111836641A (fr)
AU (1) AU2018389787A1 (fr)
BR (1) BR112020011976A2 (fr)
CA (1) CA3086327A1 (fr)
ES (1) ES2963179T3 (fr)
IL (1) IL275427B2 (fr)
JO (1) JOP20200153A1 (fr)
MA (1) MA51311A (fr)
MX (3) MX2020006480A (fr)
PH (1) PH12020550924A1 (fr)
SG (1) SG11202005895QA (fr)
WO (1) WO2019123252A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10538786B2 (en) 2016-04-13 2020-01-21 Janssen Pharmaceuticals, Inc. Recombinant arterivirus replicon systems and uses thereof
EP3526332B1 (fr) 2016-10-17 2024-06-26 Janssen Pharmaceuticals, Inc. Système réplicon recombinant de virus et leurs utilisations
CA3045650A1 (fr) 2016-12-05 2018-06-14 Janssen Pharmaceuticals, Inc. Compositions et methodes d'activation d'expression genique
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
BR112020014525A2 (pt) 2018-01-19 2020-12-08 Janssen Pharmaceuticals, Inc. Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes
US12331076B2 (en) 2018-10-08 2025-06-17 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
WO2020255018A1 (fr) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
CA3143632A1 (fr) * 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Molecules d'arn a auto-replication pour vaccins contre le virus de l'hepatite b (vhb) et utilisations associees
WO2022133230A1 (fr) * 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
AU2022311974A1 (en) * 2021-07-16 2024-02-22 Mcmaster University Viral vaccine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
CA2168583C (fr) * 1993-08-02 2007-10-02 Francis V. Chisari Peptides induisant des reactions cytotoxiques des lymphocytes t contre le virus de l'hepatite b
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
DK1023107T3 (da) 1997-04-03 2006-12-27 Electrofect As Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
HUP0004589A3 (en) 1997-06-30 2003-08-28 Centre Nat Rech Scient Improved method for transferring nucleic acid into the striped muscle and combination therefor
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
MXPA03006971A (es) * 2001-02-05 2004-05-05 Stressgen Biotechnologies Corp Tratamiento del virus de hepatitis b.
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
EP1729848B1 (fr) 2004-03-08 2015-04-29 Ichor Medical Systems Inc. Appareil ameliore pour une administration electriquement mediee d'agents therapeutiques
CA2666501C (fr) 2006-10-17 2017-03-21 Vgx Pharmaceuticals, Inc. Dispositifs d'electroporation et leurs procedes d'utilisation pour l'electroporation de cellules de mammiferes
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
EP3266464A3 (fr) * 2011-02-12 2018-03-14 Globeimmune, Inc. Thérapeutique à base de levure pour infection chronique par l'hépatite b
TWI575070B (zh) * 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
KR102535764B1 (ko) 2016-03-28 2023-05-30 아이커 메디칼 시스템스 인코포레이티드 치료제를 전달하기 위한 장치
EP3439696A4 (fr) * 2016-04-06 2019-12-25 University of Washington Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant l'antigène nucléocapsidique du vhb

Also Published As

Publication number Publication date
BR112020011976A2 (pt) 2020-11-24
ES2963179T3 (es) 2024-03-25
MX2020011802A (es) 2020-12-07
IL275427B1 (en) 2023-12-01
JOP20200153A1 (ar) 2022-10-30
AU2018389787A1 (en) 2020-06-25
KR20200101416A (ko) 2020-08-27
MX2020011804A (es) 2020-12-07
JP2021509107A (ja) 2021-03-18
EP4272833A3 (fr) 2024-01-10
EP3727445A1 (fr) 2020-10-28
EP4272833A2 (fr) 2023-11-08
CA3086327A1 (fr) 2019-06-27
EP3727445B1 (fr) 2023-08-16
CN111836641A (zh) 2020-10-27
IL275427B2 (en) 2024-04-01
IL275427A (en) 2020-08-31
EP3727445C0 (fr) 2023-08-16
MX2020006480A (es) 2020-09-22
JP7317017B2 (ja) 2023-07-28
SG11202005895QA (en) 2020-07-29
PH12020550924A1 (en) 2021-05-31
WO2019123252A1 (fr) 2019-06-27

Similar Documents

Publication Publication Date Title
MA51311A (fr) Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
MA50813A (fr) Vaccins contre le virus d'epstein-barr
EP3325097A4 (fr) Compositions et agents contre le virus de l'hépatite b et utilisations de ceux-ci
MA49463A (fr) Vaccin contre le virus de l'herpès simplex
IL274298A (en) Amino-thaizole substituted indole-z-carboxamides and compositions comprising same for use against the hepatitis b virus (hbv)
EP3439696A4 (fr) Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant l'antigène nucléocapsidique du vhb
MA55581A (fr) Traitement combiné avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hépatite b
SG10202007323VA (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof
EP3334833A4 (fr) Vaccins du virus de l'herpès de dinde recombinant et utilisations de celui-ci
MA56535A (fr) Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
IL275429A (en) Methods and device for administering hepatitis virus HBV vaccines) B)
IL275849A (en) Influenza virus vaccines and their uses
MA56534A (fr) Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)
MA51312A (fr) Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)
IL255366A0 (en) Reagents for the treatment of hepatitis B infection and their use
IL273093A (en) Combination of drugs for the treatment of hepatitis B virus type HBV patients using Parafoxvirus Obis (PPVO) and at least one other antiviral agent
EP3515929A4 (fr) Vaccins thérapeutiques contre le virus de l'hépatite b
EP3434281A4 (fr) Vaccin thérapeutique contre l'hépatite b à base de cellules de hansenula totalement recombinées et inactivées exprimant hbsag
IL277128A (en) Hepatitis B vaccines and their uses
MA45994A (fr) Vaccins contre des virus
IL290924A (en) Vaccines for hepatitis b virus
MA56524A (fr) Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
WO2014160088A3 (fr) Traitement d'infections par le virus de l'hépatite b
MA56533A (fr) Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof